Medical Developments International Limited

Symbol: MVP.AX

ASX

0.59

AUD

Market price today

  • -2.4483

    P/E Ratio

  • -0.0086

    PEG Ratio

  • 50.92M

    MRK Cap

  • 0.00%

    DIV Yield

Medical Developments International Limited (MVP-AX) Stock Price & Analysis

Shares Outstanding

86.31M

Gross Profit Margin

-0.21%

Operating Profit Margin

-0.75%

Net Profit Margin

-0.57%

Return on Assets

-0.21%

Return on Equity

-0.24%

Return on Capital Employed

-0.31%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Brent MacGregor
Full-time employees:68
City:Scoresby
Address:4 Caribbean Drive
IPO:2003-12-14
CIK:

Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers respiratory devices for sufferers of asthma and chronic obstructive pulmonary disease; Penthrox, a trauma and emergency pain relief product; and medical devices, such as CPR face shield key rings, CPR masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, OXI port carry and hand bags, oxygen resuscitation kits, oxygen therapy masks, and resuscitators. The company was incorporated in 2003 and is headquartered in Scoresby, Australia.

General Outlook

In simple terms, Medical Developments International Limited has 86.305 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep -0.215% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.750%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.574%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.211% return, is a testament to Medical Developments International Limited's adeptness in optimizing resource deployment. Medical Developments International Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.245%. Furthermore, the proficiency of Medical Developments International Limited in capital utilization is underscored by a remarkable -0.314% return on capital employed.

Stock Prices

Medical Developments International Limited's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.82, while its low point bottomed out at $0.77. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Medical Developments International Limited's stock market.

Liquidity Ratios

Analyzing MVP.AX liquidity ratios reveals its financial health of the firm. The current ratio of 278.17% gauges short-term asset coverage for liabilities. The quick ratio (184.12%) assesses immediate liquidity, while the cash ratio (140.72%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio278.17%
Quick Ratio184.12%
Cash Ratio140.72%

Profitability Ratios

MVP.AX profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -71.05% underscores its earnings before tax deductions. The effective tax rate stands at 19.27%, revealing its tax efficiency. The net income per EBT, 80.73%, and the EBT per EBIT, 94.73%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -75.01%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-71.05%
Effective Tax Rate19.27%
Net Income per EBT80.73%
EBT per EBIT94.73%
EBIT per Revenue-75.01%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.78, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 691.88% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding184
Days of Inventory Outstanding85
Operating Cycle138.03
Days of Payables Outstanding88
Cash Conversion Cycle50
Receivables Turnover6.92
Payables Turnover4.15
Inventory Turnover4.28
Fixed Asset Turnover2.87
Asset Turnover0.37

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.16, and free cash flow per share, -0.24, depict cash generation on a per-share basis. The cash per share value, 0.18, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.42, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.16
Free Cash Flow per Share-0.24
Cash per Share0.18
Operating Cash Flow Sales Ratio-0.42
Free Cash Flow to Operating Cash Flow Ratio1.45
Cash Flow Coverage Ratio-5.84
Short Term Coverage Ratio-38.84
Capital Expenditure Coverage Ratio-2.20
Dividend Paid and Capex Coverage Ratio-2.20
Dividend Payout Ratio0.40

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 2.66%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.03, we discern the balance between debt and equity financing. The long-term debt to capitalization, 2.65%, and total debt to capitalization, 3.11%, ratios shed light on its capital structure. An interest coverage of -279.14 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio2.66%
Debt Equity Ratio0.03
Long Term Debt to Capitalization2.65%
Total Debt to Capitalization3.11%
Interest Coverage-279.14
Cash Flow to Debt Ratio-5.84
Company Equity Multiplier1.20

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.38, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.07, reflects the portion of profit attributed to each share. The book value per share, 0.96, represents the net asset value distributed per share, while the tangible book value per share, 0.82, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.38
Net Income Per Share-0.07
Book Value Per Share0.96
Tangible Book Value Per Share0.82
Shareholders Equity Per Share0.96
Interest Debt Per Share0.03
Capex Per Share-0.09

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -11.49%, indicates top-line expansion, while the gross profit growth, -18.14%, reveals profitability trends. EBIT growth, -153.18%, and operating income growth, -153.18%, offer insights into operational profitability progression. The net income growth, 1.26%, showcases bottom-line expansion, and the EPS growth, 5.56%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-11.49%
Gross Profit Growth-18.14%
EBIT Growth-153.18%
Operating Income Growth-153.18%
Net Income Growth1.26%
EPS Growth5.56%
EPS Diluted Growth5.56%
Weighted Average Shares Growth4.11%
Weighted Average Shares Diluted Growth4.11%
Operating Cash Flow Growth11.50%
Free Cash Flow Growth15.33%
10-Year Revenue Growth per Share51.49%
5-Year Revenue Growth per Share6.19%
3-Year Revenue Growth per Share-2.86%
10-Year Operating CF Growth per Share-739.90%
5-Year Operating CF Growth per Share38.91%
3-Year Operating CF Growth per Share-133.53%
10-Year Net Income Growth per Share-526.96%
5-Year Net Income Growth per Share-4332.04%
3-Year Net Income Growth per Share-1183.56%
10-Year Shareholders Equity Growth per Share189.18%
5-Year Shareholders Equity Growth per Share125.72%
3-Year Shareholders Equity Growth per Share16.49%
10-Year Dividend per Share Growth per Share-100.00%
5-Year Dividend per Share Growth per Share-100.00%
3-Year Dividend per Share Growth per Share-100.00%
Receivables Growth129.76%
Inventory Growth24.04%
Asset Growth-7.94%
Book Value per Share Growth-19.42%
Debt Growth-7.74%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 43,211,620.475, captures the company's total value, considering both debt and equity. Income quality, 2.94, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 1.01, gauges operational efficiency, while the research and development to revenue, 0.73%, highlights investment in innovation. The ratio of intangibles to total assets, 11.21%, indicates the value of non-physical assets, and capex to operating cash flow, 46.47%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value43,211,620.475
Income Quality2.94
Sales General and Administrative to Revenue1.01
Research and Development to Revenue0.73%
Intangibles to Total Assets11.21%
Capex to Operating Cash Flow46.47%
Capex to Revenue-23.70%
Capex to Depreciation-246.23%
Stock-Based Compensation to Revenue3.89%
Graham Number1.20
Return on Tangible Assets-5.77%
Graham Net Net0.09
Working Capital27,214,000
Tangible Asset Value69,043,000
Net Current Asset Value14,591,000
Average Receivables7,589,000
Average Payables11,346,000
Average Inventory7,741,500
Days Sales Outstanding101
Days Payables Outstanding140
Days of Inventory On Hand88
ROIC-18.10%
ROE-0.07%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.62, and the price to book ratio, 0.62, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.40, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -2.28, and price to operating cash flows, -3.32, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio0.62
Price to Book Ratio0.62
Price to Sales Ratio1.40
Price Cash Flow Ratio-3.32
Price Earnings to Growth Ratio-0.01
Enterprise Value Multiple-2.73
Price Fair Value0.62
Price to Operating Cash Flow Ratio-3.32
Price to Free Cash Flows Ratio-2.28
Price to Tangible Book Ratio0.80
Enterprise Value to Sales1.34
Enterprise Value Over EBITDA-2.52
EV to Operating Cash Flow-2.62
Earnings Yield-8.59%
Free Cash Flow Yield-36.99%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Medical Developments International Limited (MVP.AX) on the ASX in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -2.448 in 2024.

What is the ticker symbol of Medical Developments International Limited stock?

The ticker symbol of Medical Developments International Limited stock is MVP.AX.

What is company IPO date?

IPO date of Medical Developments International Limited is 2003-12-14.

What is company current share price?

Current share price is 0.590 AUD.

What is stock market cap today?

The market cap of stock today is 50920068.000.

What is PEG ratio in 2024?

The current -0.009 is -0.009 in 2024.

What is the number of employees in 2024?

In 2024 the company has 68.